Knowledge, Practice and Attitudes Regarding Substance Use Disorder Treatment and Harm Reduction Strategies Among Pharmacists: a Scoping Review Protocol

Overview

Journal BMJ Open

Specialty General Medicine

Date 2024 Feb 28

PMID 38418243

Authors

Elle Pope

Megan McCullough

Jason G Smith

Bo Kim

Affiliations

Soon will be listed here.

Abstract

Introduction: Pharmacists provide a spectrum of services and comprehensive medication management for patients with substance use disorders (SUDs) with many providing timely and increased access to care for patients. Prior studies have evaluated other healthcare professionals' attitudes, knowledge and practice in regard to SUD treatment and harm reduction services. However, no reviews to date summarise the available literature on the attitudes, knowledge and practice in regard to SUD treatment and harm reduction services from the pharmacist perspective. This scoping review aims to systematically map the extent, range and nature of available evidence and identify and describe gaps in knowledge, practice and attitudes towards SUD treatment among pharmacists with the goal of providing information for meaningful integration of pharmacists into SUD care.

Methods And Analysis: We will use the framework proposed by Arksey and O'Malley (2005) updated with recommendations by Levac (2010) and the Joanna Briggs Institute (2020). The protocol is registered via Open Science Framework (https://osf.io/92dek). We will search for peer-reviewed literature containing empirical evidence investigating SUD treatment or harm reduction with outcomes pertaining to the knowledge, practice or attitudes of pharmacists. Findings will be guided and assessed by research objectives and summarised using descriptive statistics and thematically for quantitative and qualitative findings, respectively. This review will be conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews.

Ethics And Dissemination: Our findings will provide crucial information and support for future interventions and programmes which aim to meaningfully integrate pharmacists into SUD care. We will disseminate findings at conferences and publish in a peer-reviewed journal. In addition, we will integrate feedback on search strategy, data extraction and our dissemination approach from multidisciplinary collaborators including those within our team's institution and outside experts with clinical or administrative knowledge in SUD care.

References

Hagemeier N, Alamian A, Murawski M, Pack R . Factors associated with provision of addiction treatment information by community pharmacists. J Subst Abuse Treat. 2014; 52:67-72. DOI: 10.1016/j.jsat.2014.11.006. View

Sawangjit R, Khan T, Chaiyakunapruk N . Effectiveness of pharmacy-based needle/syringe exchange programme for people who inject drugs: a systematic review and meta-analysis. Addiction. 2016; 112(2):236-247. DOI: 10.1111/add.13593. View

Brown A . Health professionals' attitudes toward medications for opioid use disorder. Subst Abus. 2021; 43(1):598-614. DOI: 10.1080/08897077.2021.1975872. View

Barnett B, Morris N . Pharmacy Access to Sterile Injection Supplies for People Who Inject Drugs. JAMA Intern Med. 2020; 181(2):153-154. DOI: 10.1001/jamainternmed.2020.6840. View

Dimitropoulos E, Bertucci S, Wong K . Integration of a clinical pharmacy specialist into a substance use disorder intensive outpatient treatment program to improve prescribing rates of alcohol use disorder pharmacotherapy. Subst Abus. 2018; 39(2):190-192. DOI: 10.1080/08897077.2018.1449172. View

Ritter A, Cameron J . A review of the efficacy and effectiveness of harm reduction strategies for alcohol, tobacco and illicit drugs. Drug Alcohol Rev. 2006; 25(6):611-24. DOI: 10.1080/09595230600944529. View

Tricco A, Lillie E, Zarin W, OBrien K, Colquhoun H, Levac D . PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018; 169(7):467-473. DOI: 10.7326/M18-0850. View

Levac D, Colquhoun H, OBrien K . Scoping studies: advancing the methodology. Implement Sci. 2010; 5:69. PMC: 2954944. DOI: 10.1186/1748-5908-5-69. View

Manolakis P, Skelton J . Pharmacists' contributions to primary care in the United States collaborating to address unmet patient care needs: the emerging role for pharmacists to address the shortage of primary care providers. Am J Pharm Educ. 2011; 74(10):S7. PMC: 3058447. DOI: 10.5688/aj7410s7. View

10.

Adams J, Chopski N, Adams A . Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the Mainstreaming Addiction Treatment (MAT) Act. J Am Pharm Assoc (2003). 2023; 63(5):1495-1499. DOI: 10.1016/j.japh.2023.06.001. View

11.

Madden E, Prevedel S, Light T, Sulzer S . Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review. Subst Use Misuse. 2021; 56(14):2181-2201. DOI: 10.1080/10826084.2021.1975749. View

12.

Watson T, Hughes C . Pharmacists and harm reduction: A review of current practices and attitudes. Can Pharm J (Ott). 2013; 145(3):124-127.e2. PMC: 3567507. DOI: 10.3821/145.3.cpj124. View

13.

Gugala E, Briggs O, Moczygemba L, Brown C, Hill L . Opioid harm reduction: A scoping review of physician and system-level gaps in knowledge, education, and practice. Subst Abus. 2022; 43(1):972-987. DOI: 10.1080/08897077.2022.2060423. View

14.

Peters M, Marnie C, Tricco A, Pollock D, Munn Z, Alexander L . Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020; 18(10):2119-2126. DOI: 10.11124/JBIES-20-00167. View

15.

Muzyk A, Smothers Z, Collins K, MacEachern M, Wu L . Pharmacists' attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature. Subst Abus. 2019; 40(4):476-483. PMC: 6920531. DOI: 10.1080/08897077.2019.1616349. View

16.

Wu L, John W, Ghitza U, Wahle A, Matthews A, Lewis M . Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network. Addiction. 2021; 116(7):1805-1816. PMC: 8172420. DOI: 10.1111/add.15353. View

17.

Chiarello E . Nonprescription syringe sales: Resistant pharmacists' attitudes and practices. Drug Alcohol Depend. 2016; 166:45-50. DOI: 10.1016/j.drugalcdep.2016.06.023. View

18.

Smart R, Pardo B, Davis C . Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States. Addiction. 2020; 116(1):6-17. PMC: 8051142. DOI: 10.1111/add.15163. View

19.

Ijioma S, Pontinha V, Holdford D, Carroll N . Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree. J Manag Care Spec Pharm. 2021; 27(2):137-146. PMC: 10391166. DOI: 10.18553/jmcp.2021.27.2.137. View

20.

Bachyrycz A, Shrestha S, Bleske B, Tinker D, Bakhireva L . Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery. Subst Abus. 2016; 38(1):55-60. PMC: 5623593. DOI: 10.1080/08897077.2016.1184739. View